A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Colorectal Neoplasms Clinical Trial

Official title:

A Phase 1/2, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00841191
• Other study ID #: CR015580
• Secondary ID: CNTO328STM200120
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: February 9, 2009
• Last updated: May 13, 2014
• Start date: March 2009
• Est. completion date: April 2011

Study information

• Verified date: May 2014
• Source: Centocor, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationBelgium: Federal Agency for Medicinal Products and Health ProductsFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab monotherapy in participants with ovarian cancer and with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors.

Description:

This is a 2-part, Phase 1/2, open-label (all people know the identity of the intervention), multiple-dose and dose-escalation study of intravenous (directly into a vein) siltuximab in participants with malignant solid tumors. The study tests the safety and effectiveness of the experimental drug, siltuximab, in participants with advanced cancer (abnormal tissue that grows and spreads in the body). This study also tests how siltuximab is cleared from the body and how the body reacts to it. For this reason blood tests will be performed and some characteristics of the tumor will be analyzed. Siltuximab will be given by intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour. In Phase 1 (Cohort 1-4) doses will be administered in a range of 2.8-15 milligram per kilogram (mg/kg). Cohort 5 of Phase 1 will receive the recommended dose and schedule as determined from Cohort 1-4. Participants in Phase 1 (Cohort 1-4) will receive 4 administrations of siltuximab over a 10-13 week period, while participants in Cohort 5 and Phase 2 will receive 12 administrations over a 33 week period. Follow-up visits up to 12 weeks after last dose will be scheduled. Participants may then be contacted for up to 1 year after the last dose for follow-up survival and disease status information. Efficacy will primarily be evaluated as per response evaluation criteria in solid tumors (RECIST) criteria. Participants' safety will be monitored at every visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologic (pertaining to body tissues) or cytologic (pertaining to cells) documentation of malignancy (cancer or other progressively enlarging and spreading tumor) as follows: malignant solid tumors (Cohort 1-4 only); Cohorts 5 and Phase 2: epithelial (tissue covering outer layers of most body organs and parts) ovarian cancers (abnormal tissue growth) that have progressed on or after standard therapy, or for which there is no effective therapy or platinum resistant and taxane resistant, defined as progression on or within 6 months of completing therapy with taxane and platinum either alone or in combination (unless contraindications for taxane or platinum exist), and for which there is no effective therapy, or participants with known KRAS mutant tumors or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC) or head and neck (H&N) cancer that are refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy and all participants must have received at least 1 line of standard chemotherapy

• Eastern cooperative oncology group (ECOG) performance status score less than or equal to 2

• Participants must have recovered from reversible toxicity (any harmful effect of a drug or poison) of previous treatment to less than or equal to grade 1 or an acceptable baseline

• Women of child bearing potential must have a negative pregnancy test at screening

• Cohort 5 and Phase 2 cohorts must have evaluable or measurable disease (defined by response evaluation criteria in solid tumors [RECIST], as applicable)

Exclusion Criteria:

• Received any prior systemic therapy or had major surgery for the cancer under study within 4 weeks (in the case of nitrosoureas and mitomycin C within 6 weeks) prior to first siltuximab administration

• Prior anti-interleukin 6 (IL-6) targeted therapy

• Serious concurrent illness or history of uncontrolled heart disease such as: unstable angina (chest pain due to decreased oxygen being supplied to the heart), congestive heart failure (failure of the heart resulting in fluid build-up in the lungs, other body tissues, or both), myocardial infarction (heart attack) within preceding 12 months, clinically significant rhythm or conduction abnormality

• Participants with known allergies (over sensitivity to a substance) or clinically significant reactions to murine, chimeric, or human proteins

• Any uncontrolled medical condition, including the presence of laboratory abnormalities, that places the participant at unacceptable risk by participating in the study or confounds the ability to interpret data from the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Head and Neck Neoplasms
• Lung Neoplasms
• Neoplasms
• Ovarian Neoplasms
• Pancreatic Neoplasms

Intervention

Drug:
• CNTO 328; Anti-interleukin-6 monoclonal antibody
Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
• CNTO 328; Anti-interleukin-6 monoclonal antibody
Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
• CNTO 328; Anti-interleukin-6 monoclonal antibody
Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
• CNTO 328; Anti-interleukin-6 monoclonal antibody
Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
• CNTO 328; Anti-interleukin-6 monoclonal antibody
Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
• CNTO 328; Anti-interleukin-6 monoclonal antibody
Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
• CNTO 328; Anti-interleukin-6 monoclonal antibody
Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Centocor, Inc.

Countries where clinical trial is conducted

United States,  Belgium,  France,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Clinical Benefit Response (CBR)	The CBR is a confirmed complete response (CR), partial response (PR), or stable disease (SD) lasting at least for 6 weeks as per response evaluation criteria in solid tumors (RECIST) criteria. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least 30 percent decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since treatment started.	Baseline until disease progression or withdrawal of consent, assessed every 9 weeks up to Week 4 after last dose administration	No
Secondary	Percentage of Participants With Overall Response	Overall response is defined as a confirmed CR or PR using RECIST criteria. CR is defined as disappearance of all target lesions and non-target lesions and normalization of tumor marker level, and PR is defined as at least 30 percent decrease in sum of the LD of target lesions, taking as reference the baseline sum LD.	Baseline until disease progression or withdrawal of consent, assessed every 9 weeks up to Week 4 after last dose administration	No
Secondary	Number of Participants With Tumor Marker Response	According to gynecologic cancer intergroup criteria (GCIC), tumor marker response is defined as at least a 50 percent reduction in tumor marker which must be confirmed and maintained for at least 4 weeks. Tumor marker response is assessed using cancer antigen (CA-125), carcinoembryonic antigen (CEA), CA-19.9 and other markers as available	Baseline until disease progression or withdrawal of consent, assessed every 9 weeks up to Week 4 after last dose administration	No
Secondary	Percentage of Participants With Hemoglobin (Hb) Response	The Hb response is defined by an increase of at least 1 gram per deciliter (g/dL) over baseline observed at least once in the absence of transfusion or erythropoietin stimulating agents.	Baseline up to Week 4 after last dose administration	No
Secondary	Progression Free Survival (PFS)	The PFS is the time interval between first administration of siltuximab and the first documented sign of progression (at least a 20 percent increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new target or non-target lesions as per RECIST) or death, whichever occurs first.	Baseline until disease progression or death, assessed every 9 weeks up to Week 4 after last dose administration	No
Secondary	Overall Survival (OS)	The OS is the interval between first administration of siltuximab and the participant's death from any cause.	From first dose administration until death, assessed every 3 months up to 12 months after last dose administration	No
Secondary	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score	The EORTC QLQ-C30 is used to measure physical function, general health, and global health, as well as participant-reported impression of global quality of life. Symptoms in the scale include: fatigue, pain, and sleep disturbance. It contains 28 items scored using a Likert scale from 1 (not at all) to 4 (very much). 2 additional items are scored from 1 (very poor) to 7 (excellent). Total score ranges from 30-126 with higher score indicating better level of functioning or greater degree of symptoms.	Baseline up to 4 weeks after last dose administration	No
Secondary	Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-OV28) Score at Week 4 After Last Dose Administration	The EORTC QLQ-OV28 covers side effects of therapy; activity limitation attributable to disease; hormonal symptoms; body image; difficulty with specific bodily functions; and sexual functioning. It contains 28 items scored using a Likert scale from 1 (not at all) to 4 (very much) with a recall period of the past week or, in the final segment, the past 4 weeks. Total score ranges from 28-112 with higher score indicating better level of functioning or greater degree of symptoms.	Baseline and Week 4 after last dose administration	No
Secondary	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf])	Area under the serum concentration versus time curve from time zero to infinity with extrapolation of the terminal phase will be calculated; samples for the determination of siltuximab serum concentration will be collected from 0 hour (h) (pre-dose) to 24h (post-dose) on Day (D) 1 up to Week 12 (Wk12) after last dose administration for all cohorts.	Cohort1-4:0,1,4,6,24h post-dose on D1,8,15,22; D1 of extended treatment; Cohort1,2:0,1h post-dose on D28,42,56; Cohort3,4:D28,49,70; Cohort5-7:0,1,2h post-dose on D1,8,15; 0,1h post-dose on D21,42,63,84,105,168,231; up to Wk12 after last dose (Cohort1-7)	No
Secondary	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC[0-t])	Area under the serum concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (AUC[0-t]) was calculated.	Cohort1-4:0,1,4,6,24h post-dose on D1,8,15,22; D1 of extended treatment; Cohort1,2:0,1h post-dose on D28,42,56; Cohort3,4:D28,49,70; Cohort5-7:0,1,2h post-dose on D1,8,15; 0,1h post-dose on D21,42,63,84,105,168,231; up to Wk12 after last dose (Cohort1-7)	No
Secondary	Minimum Observed Serum Concentration at Steady-State (Cmin,ss)	The Cmin,ss is the minimum observed serum concentration during a dosing interval at steady-state (time at which serum concentration does not change with time).	Cohort1-4:0,1,4,6,24h post-dose on D1,8,15,22; D1 of extended treatment; Cohort1,2:0,1h post-dose on D28,42,56; Cohort3,4:D28,49,70; Cohort5-7:0,1,2h post-dose on D1,8,15; 0,1h post-dose on D21,42,63,84,105,168,231; up to Wk12 after last dose (Cohort1-7)	No
Secondary	Maximum Observed Serum Concentration (Cmax)	The Cmax is the maximum observed serum concentration of siltuximab.	Cohort1-4:0,1,4,6,24h post-dose on D1,8,15,22; D1 of extended treatment; Cohort1,2:0,1h post-dose on D28,42,56; Cohort3,4:D28,49,70; Cohort5-7:0,1,2h post-dose on D1,8,15; 0,1h post-dose on D21,42,63,84,105,168,231; up to Wk12 after last dose (Cohort1-7)	No
Secondary	Terminal Elimination Half Life (t1/2)	Terminal elimination half-life is the time measured for the serum concentration to decrease to half value.	Cohort1-4:0,1,4,6,24h post-dose on D1,8,15,22; D1 of extended treatment; Cohort1,2:0,1h post-dose on D28,42,56; Cohort3,4:D28,49,70; Cohort5-7:0,1,2h post-dose on D1,8,15; 0,1h post-dose on D21,42,63,84,105,168,231; up to Wk12 after last dose (Cohort1-7)	No
Secondary	Total Systemic Clearance (CL)	Total systemic CL is calculated by dividing the dose by area under the curve from time 0 to extrapolated infinite time (AUCinf).	Cohort1-4:0,1,4,6,24h post-dose on D1,8,15,22; D1 of extended treatment; Cohort1,2:0,1h post-dose on D28,42,56; Cohort3,4:D28,49,70; Cohort5-7:0,1,2h post-dose on D1,8,15; 0,1h post-dose on D21,42,63,84,105,168,231; up to Wk12 after last dose (Cohort1-7)	No
Secondary	Volume of Distribution at Steady State (Vss)	The Vss is calculated by multiplying mean residence time (MRT) with systemic clearance (CL). MRT is the time when 63.2 percent of an intravenous dose has been eliminated after single dose administration.	Cohort1-4:0,1,4,6,24h post-dose on D1,8,15,22; D1 of extended treatment; Cohort1,2:0,1h post-dose on D28,42,56; Cohort3,4:D28,49,70; Cohort5-7:0,1,2h post-dose on D1,8,15; 0,1h post-dose on D21,42,63,84,105,168,231; up to Wk12 after last dose (Cohort1-7)	No
Secondary	Percent Change From Baseline in C-Reactive Protein (CRP) Level	The CRP levels are determined using high sensitive CRP assay and percent change from baseline is calculated at each time point.	Baseline; Day (D) 1,8,15 (post-dose) for cohort 1 to 7; Day 22 (post-dose), 28 (pre-dose) for cohort 1 to 4; Day 42,56 (pre-dose) for cohort 1, 2; Day 49,70 (pre-dose) for cohort 3, 4; Day 21,42,63,84,105,126,147,168,189,210 (pre-dose) for cohort 5 to 7	No
Secondary	Percent Change From Baseline in Inflammatory Cytokines Level	Percent change from baseline in the levels of inflammatory (pertaining to pain, redness and swelling) markers for interferon gamma (IFN-g), interleukin 1 beta (IL1b), IL-2, IL-5, IL-8, IL10, IL12, and tumor necrosis factor alpha (TNFa) is calculated.	Baseline; Day 8 and 15 (post-dose) for cohort (C) 1 to 7; Day 22 (post-dose) and 28 (pre-dose) for cohort 1 to 4; Day 42 and 56 (pre-dose) for cohort 1 and 2; Day 49 and 70 (pre-dose) for cohort 3 and 4; Day 21, 42 and 63 (pre-dose) for cohort 5 to 7	No
Secondary	Percent Change From Baseline in the Angiogenesis Related Factors Level	Percent change from baseline in the level of markers associated with angiogenesis related factors (vascular endothelial growth factor [VEGF], vascular endothelial growth factor receptor [VEGFR], and basic fibroblast growth factor [bFGF]) is calculated.	Baseline; Day 8 and 15 (post-dose) for cohort 1 to 7; Day 22 (post-dose) and 28 (pre-dose) for cohort 1 to 4; Day 42 and 56 (pre-dose) for cohort 1 and 2; Day 49 and 70 (pre-dose) for cohort 3 and 4; Day 21, 42 and 63 (pre-dose) for cohort 5 to 7	No
Secondary	Percent Change From Baseline in Interleukin 6 Receptor (IL-6R) Subunits Level	Percent change from baseline in the level of ligand-binding subunit of the IL-6R, soluble GP80 (sGP80) and signal-transducing subunit of the IL-6R, soluble GP130 (sGP130) is calculated.	Baseline; Day 8 and 15 (post-dose) for cohort 1 to 7; Day 28 (pre-dose) for cohort 1 to 4; Day 42 and 56 (pre-dose) for cohort 1 and 2; Day 49 and 70 (pre-dose) for cohort 3 and 4; Day 21, 42 and 63 (pre-dose) for cohort 5 to 7	No
Secondary	Number of Participants Assessed Positive for Antibodies to Siltuximab	Number of participants who are tested positive for antibodies (type of protein that helps to protect the body against foreign matter, such as bacteria and viruses) to siltuximab is reported.	Day 1 (pre-dose) up to Week 12 after last dose administration	No
Secondary	Percent Change From Baseline in Hepcidin Level	Hepcidin is a liver-produced iron-regulatory peptide hormone (substance made by a gland in the body that regulates another part of the body) that is implicated in anemia (decreased number of red blood cells) of inflammation (pain, redness and swelling). Percent change from baseline in hepcidin (marker of anemia and iron metabolism) level is calculated.	Baseline; Day 8 and 15 (post-dose) for cohort 1 to 7; Day 22 (post-dose) and 28 (pre-dose) for cohort 1 to 4; Day 42 and 56 (pre-dose) for cohort 1 and 2; Day 49 and 70 (pre-dose) for cohort 3 and 4; Day 21, 42 and 63 (pre-dose) for cohort 5 to 7	No

External Links

•   A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid Tumors